Endometrial cancer is divided into two categories and is one of the most common cancers of the uterus. Type 1 is the most prevalent (70?80%) and has a better prognosis because it is limited to the uterus. Every year, 319.500 cases were reported worldwide, resulting in 76.000 deaths. Endometrial cancer is divided into ten major groups based on histology and four groups depending on the likelihood of recurrence, according to the World Health Organization. Age (post-menopause), race, genetics, lifestyle, parity, diabetes, hypertension, unopposed estrogen therapy, early menarche, and delayed menopause are only a few of the risk factors. Women over 45 years of age who have abnormal uterine bleeding should be evaluated with a histological examination and/or ultrasound, according to the American College of Obstetricians and Gynecologists (ACOG). The ultimate test for diagnosis is an endometrial biopsy. Following that, imaging modalities could be used to help with staging. FIGO stage, histological subtypes, tumor grade, myometrial invasion, lymphovascular space invasion, and age are all prognostic variables. Surgical and non-surgical treatment options are commonly used. Lymphadenectomy is not generally indicated in patients with a low risk of recurrence because of the danger of complications, especially in the elderly.